Dr Mark Socinski reviews data for first-line dual immunotherapy from the CheckMate-227, CheckMate-9LA, and POSEIDON studies, which demonstrated overall survival advantages in patients with metastatic NSCLC treated with nivolumab plus ipilimumab or durvalumab plus tremelimumab compared with standard-of-care chemotherapy.
Medical Oncologist, Thoracic Cancer
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Executive Medical Director
AdventHealth Cancer Institute
Orlando, FL
Related Items
Faculty Perspectives: Comprehensive Biomarker Testing in NSCLC: Opportunities to Advance Precision Medicine published on June 27, 2022
Conference Correspondent published on December 16, 2021 in Dual IO 2021 Year in Review
Conference Correspondent published on December 16, 2021 in Dual IO 2021 Year in Review
Conference Correspondent published on December 15, 2021 in Dual IO 2021 Year in Review